Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

17.37 -0.52 (-2.91%)
Streaming Delayed Price Updated: 11:48 AM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 317,588
Open 17.48
Bid (Size) 17.35 (2)
Ask (Size) 17.39 (3)
Prev. Close 17.89
Today's Range 17.21 - 18.00
52wk Range 13.53 - 35.25
Shares Outstanding 79,199,501
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire

Performance

YTD
-29.7%
-29.7%
1 Month
-4.8%
-4.8%
3 Month
-48.1%
-48.1%
6 Month
-28.0%
-28.0%
1 Year
-30.1%
-30.1%

More News

Read More
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
Analyst Expectations For Beam Therapeutics's Future
Via Benzinga
10 Analysts Assess Beam Therapeutics: What You Need To Know
Via Benzinga
Why Beam Therapeutics Stock Tanked on Tuesday
Via The Motley Fool
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
From Beam Therapeutics
Via GlobeNewswire
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
Via Benzinga
Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease
Via Benzinga
Exposures Product Safety
Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox
Via Benzinga
Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed'
Via Benzinga
This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Via Benzinga
Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock
Via Benzinga
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen
Via Benzinga
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
Via Benzinga
Beam Therapeutics Announces Pricing of Underwritten Offering
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14%
Via Benzinga
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies
Via Benzinga
Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday
Via Benzinga

Frequently Asked Questions

Is Beam Therapeutics Inc. - Common Stock publicly traded?
Yes, Beam Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Beam Therapeutics Inc. - Common Stock trade on?
Beam Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Beam Therapeutics Inc. - Common Stock?
The ticker symbol for Beam Therapeutics Inc. - Common Stock is BEAM on the Nasdaq Stock Market
What is the current price of Beam Therapeutics Inc. - Common Stock?
The current price of Beam Therapeutics Inc. - Common Stock is 17.37
When was Beam Therapeutics Inc. - Common Stock last traded?
The last trade of Beam Therapeutics Inc. - Common Stock was at 05/19/25 11:48 AM ET
What is the market capitalization of Beam Therapeutics Inc. - Common Stock?
The market capitalization of Beam Therapeutics Inc. - Common Stock is 1.38B
How many shares of Beam Therapeutics Inc. - Common Stock are outstanding?
Beam Therapeutics Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.